Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag201 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Mackenzie J Pearson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Lipids, Metabolome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D.
Objective
Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
Methods
Metabolomics and lipidomics were performed in fasting samples from 2 randomized, placebo-controlled phase 2 trials as a post hoc exploratory analysis. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. There were 282 and 213 participants in the obesity and T2D trials, respectively and the intervention(s) received were: Obesity trial: retatrutide (1, 4, 8, and 12 mg) or placebo; T2D trial: retatrutide (0.5, 4, 8, and 12 mg) or placebo or dulaglutide (1.5 mg). The main outcome measure(s) were changes in metabolite and lipid levels with retatrutide treatment against baseline levels and placebo using multiplicity correction.
Results
At both primary and study endpoints for both populations, higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid–derived long-chain acylcarnitines. Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D. Retatrutide treatment was also associated with changes in metabolites associated with insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These changes were found in both study populations and sustained across study endpoints.
Conclusion
Retatrutide was associated with changes in 2 metabolic clusters related to fatty acid oxidation and insulin resistance in a direction associated with improved metabolic health and reduced cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA.
- Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC 27705, USA.
- Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC 27705, USA.
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27705, USA.
ORCID-Profile: Valentina Pirro
Förderung
- Eli Lilly and Company
Zitieren
APA
Pearson, M. J., Willency, J. A., Lin, Y., Abadi, A., Hartman, M. L., Coskun, T., Ruotolo, G., Duffin, K. L., Haupt, A., Newgard, C. B., & Pirro, V. (2026). Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag201
Vancouver
Pearson MJ, Willency JA, Lin Y, Abadi A, Hartman ML, Coskun T, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag201
BibTeX
@article{Pearson2026,
author = {Pearson, Mackenzie J and Willency, Jill A and Lin, Yanzhu and Abadi, Arkan and Hartman, Mark L and Coskun, Tamer and Ruotolo, Giacomo and Duffin, Kevin L and Haupt, Axel and Newgard, Christopher B and Pirro, Valentina},
title = {Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag201}
}
EUVIMED